The Next Frontier for Biosimilars Intrusion

Posted by Will Gatziolis on Jul 25, 2019 8:00:00 AM

Eric Detwiler, Sandeep Sangwan and Christina Corridon co-wrote this blog post with Will Gatziolis.

As of mid-2019, the U.S. market has seen considerable competition from biosimilars in supportive oncology care. The next U.S. biosimilar frontier is therapeutic oncology care, where Genentech’s big trio—Rituxan, Herceptin and Avastin—will likely attempt to hold their ground against biosimilars. Reference product manufacturers and biosimilar manufacturers have been closely monitoring U.S. biosimilar uptake to understand how this market is likely to evolve, but diverse go-to-market and defense strategies may leave us with more questions than answers. As pricing pressure mounts in the U.S., so does pressure on biosimilar uptake, leaving reference product manufacturers and biosimilar manufacturers alike wondering what biosimilar uptake will look like in the therapeutic oncology space, and how much price erosion can be expected due to biosimilar competition.


>
Read More

In Conversation With ZS Experts: How to Compete When You’re Not the First or Best on the Market

Posted by Matilda Males on Mar 15, 2019 10:21:58 AM

Jennifer Curtis co-wrote this blog post with Matilda Males.

While customer experience is not a new concept in pharma, it has been relatively absent as a core strategy for many of the leading oncology companies. Why? Until recently, it hasn’t been necessary. Twenty years ago, the oncology market was dominated by a few key players whose success was driven by single blockbuster drugs that generated years of high returns. Today, the market has exploded. The combination of high unmet need and promising revenue potential has resulted in companies of all sizes dipping their toes into the oncology market. Fourteen of the largest pharma companies have one-third of their late-stage R&D focused exclusively on oncology, and almost 700 companies have one or more assets in late-stage development, according to IQVIA’s 2018 Global Oncology Trends report. We’re also seeing a decline in the duration of clinical trials and faster drug approvals, leading to shorter development life cycles. At the same time, there are fewer clinically differentiated assets that are competing within the same space and with high prices.


>
Read More